PDF(Pubmed)
Abstract：
UNASSIGNED: Cholangiocarcinoma (CCA) is an aggressive disease with limited treatment options. Despite substantial efforts to explore better regimens, gemcitabine-based chemotherapy has been the standard first-line treatment for decades. With the growing field of precision medicine, biomarker-guided treatments are gaining popularity. MET alteration is a frequent occurrence in various cancer types, making it a promising target.
UNASSIGNED: A 53-year-old man visited our hospital with a complaint of upper abdominal pain. Advanced CCA was diagnosed based on the biopsy of the metastatic lymph nodes and immunohistochemistry. Next-generation sequencing revealed MET amplification. As the patient was intolerant to traditional chemotherapy, savolitinib (a c-MET inhibitor) was administered. Partial response was achieved, and the treatment was well tolerated. After 1 year, the patient developed progressive disease, to which the emergence of epidermal growth factor receptor amplification may have contributed.
UNASSIGNED: Our study verified the therapeutic value of a c-MET inhibitor in advanced CCA-harboring MET amplification and provides an alternative strategy for patients who are intolerant to chemotherapy.
UNASSIGNED: A 53-year-old man visited our hospital with a complaint of upper abdominal pain. Advanced CCA was diagnosed based on the biopsy of the metastatic lymph nodes and immunohistochemistry. Next-generation sequencing revealed MET amplification. As the patient was intolerant to traditional chemotherapy, savolitinib (a c-MET inhibitor) was administered. Partial response was achieved, and the treatment was well tolerated. After 1 year, the patient developed progressive disease, to which the emergence of epidermal growth factor receptor amplification may have contributed.
UNASSIGNED: Our study verified the therapeutic value of a c-MET inhibitor in advanced CCA-harboring MET amplification and provides an alternative strategy for patients who are intolerant to chemotherapy.
摘要：
■胆管癌（CCA）是一种侵袭性疾病，治疗选择有限。尽管努力探索更好的治疗方案，以吉西他滨为基础的化疗几十年来一直是标准的一线治疗方法.随着精准医学领域的不断发展,生物标志物指导的治疗越来越受欢迎。MET改变在各种癌症类型中经常发生，使它成为一个有希望的目标。
■一名53岁的男子主诉上腹痛到我院就诊。根据转移性淋巴结的活检和免疫组织化学诊断晚期CCA。下一代测序显示MET扩增。由于患者对传统化疗不耐受，给予savolitinib(c-MET抑制剂).取得了部分反应，治疗耐受性良好。一年后，病人发展为进行性疾病，表皮生长因子受体扩增的出现可能对此有贡献。
■我们的研究验证了c-MET抑制剂在晚期CCA-harordingMET扩增中的治疗价值，并为对化疗不耐受的患者提供了替代策略。
■一名53岁的男子主诉上腹痛到我院就诊。根据转移性淋巴结的活检和免疫组织化学诊断晚期CCA。下一代测序显示MET扩增。由于患者对传统化疗不耐受，给予savolitinib(c-MET抑制剂).取得了部分反应，治疗耐受性良好。一年后，病人发展为进行性疾病，表皮生长因子受体扩增的出现可能对此有贡献。
■我们的研究验证了c-MET抑制剂在晚期CCA-harordingMET扩增中的治疗价值，并为对化疗不耐受的患者提供了替代策略。
